Target intelligence / Profile preview

Tetanus toxin heavy chain (TTFC)

Target
TTFC
Molecular classification
Other
01

Overview

Tetanus toxin heavy chain, specifically the carboxyl-terminal fragment C (TTFC), is a non-toxic 50 kDa domain of the tetanus neurotoxin produced by Clostridium tetani. It is responsible for binding to polysialogangliosides, such as GD1b and GT1b, on the presynaptic membrane of motor neurons at the neuromuscular junction. Following binding, the heavy chain facilitates the internalization and retrograde axonal transport of the toxin into the central nervous system. Because it contains the primary receptor-binding and immunodominant epitope regions of the toxin without the enzymatic toxicity of the light chain, fragment C is a critical target for both active and passive immunization. Vaccines like the tetanus toxoid and recombinant fragment C formulations target this region to elicit neutralizing antibodies that block toxin-receptor interactions. Additionally, passive immunotherapy using tetanus immune globulin or monoclonal antibodies targets these epitopes to neutralize circulating toxin during active infection. Beyond its role in tetanus, the unique retrograde transport and neuroprotective properties of fragment C make it a valuable carrier vector for delivering therapeutic agents across the blood-brain barrier to target neurodegenerative diseases.

Other names
Tetanus toxin fragment CTetanus neurotoxin heavy chainTetanus toxin chain HTetanus toxoid heavy chain fragment CTTCTeNT-HcHc-TeTx
02

Mechanism of action

Neutralization of toxin binding to neuronal gangliosides, preventing internalization and retrograde transport of the active light chain.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionNeurodegenerative diseaseOther
05

Safety considerations

Hypersensitivity reactionsInjection site reactionsArthus-type reactionsGuillain-Barré syndromeBrachial neuritisIncomplete neutralization after neuronal internalization
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Anti-tetanus IgG antibody titer

Beyond the preview

Go deeper on Tetanus toxin heavy chain (TTFC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetanus toxin heavy chain (TTFC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call